^
BIOMARKER:
HER-2 underexpression
i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Entrez ID:
Related biomarkers:
›
HER-2 underexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 underexpression
|
Hormone Receptor Positive Breast Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: B - Late Trials
|
fam-trastuzumab deruxtecan-nxki Sensitive: B - Late Trials
|
HER-2 underexpression
|
Breast Cancer
|
HER-2 underexpression
|
Breast Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: B - Late Trials
|
fam-trastuzumab deruxtecan-nxki Sensitive: B - Late Trials
|
HER-2 underexpression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 underexpression
|
Gastroesophageal Junction Adenocarcinoma
|
fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria
|
fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria
|
HER-2 underexpression
|
HER2 Positive Breast Cancer
|
HER-2 underexpression
|
HER2 Positive Breast Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria
|
fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria
|
HER-2 underexpression
|
Gastric Cancer
|
HER-2 underexpression
|
Gastric Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria
|
fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria
|
HER-2 underexpression
|
Breast Cancer
|
HER-2 underexpression
|
Breast Cancer
|
ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria
|
ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria
|
HER-2 underexpression
|
Solid Tumor
|
HER-2 underexpression
|
Solid Tumor
|
KN046 + KN026 Sensitive: C3 – Early Trials
|
KN046 + KN026 Sensitive: C3 – Early Trials
|
HER-2 underexpression
|
LUAD
|
HER-2 underexpression
|
LUAD
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
|
HER-2 underexpression
|
HER2 Positive Breast Cancer
|
HER-2 underexpression
|
HER2 Positive Breast Cancer
|
SYD985 Sensitive: C3 – Early Trials
|
SYD985 Sensitive: C3 – Early Trials
|
HER-2 underexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 underexpression
|
Hormone Receptor Positive Breast Cancer
|
SYD985 Sensitive: C3 – Early Trials
|
SYD985 Sensitive: C3 – Early Trials
|
HER-2 underexpression
|
Breast Cancer
|
HER-2 underexpression
|
Breast Cancer
|
eribulin mesylate Sensitive: C3 – Early Trials
|
eribulin mesylate Sensitive: C3 – Early Trials
|
HER-2 underexpression
|
Breast Cancer
|
HER-2 underexpression
|
Breast Cancer
|
MRG002 Sensitive: C3 – Early Trials
|
MRG002 Sensitive: C3 – Early Trials
|
HER-2 underexpression
|
Ovarian Cancer
|
HER-2 underexpression
|
Ovarian Cancer
|
olaparib + niraparib + SYD985 Sensitive: D – Preclinical
|
olaparib + niraparib + SYD985 Sensitive: D – Preclinical
|
HER-2 underexpression
|
CRC
|
HER-2 underexpression
|
CRC
|
AMX-818 Sensitive: D – Preclinical
|
AMX-818 Sensitive: D – Preclinical
|
HER-2 underexpression
|
Breast Cancer
|
HER-2 underexpression
|
Breast Cancer
|
SAR443216 Sensitive: D – Preclinical
|
SAR443216 Sensitive: D – Preclinical
|
HER-2 underexpression
|
Breast Cancer
|
HER-2 underexpression
|
Breast Cancer
|
XMT-2056 Sensitive: D – Preclinical
|
XMT-2056 Sensitive: D – Preclinical
|
HER-2 underexpression
|
Gastric Cancer
|
HER-2 underexpression
|
Gastric Cancer
|
XMT-2056 Sensitive: D – Preclinical
|
XMT-2056 Sensitive: D – Preclinical
|
